| Background:DCM(delated cardiomyopathy) is one of the primary cardiopathy,and its etiology is not very clear yet. The main clinical manifestations includes congestive heart failure, edema, dyspnea, and so on. The therapy of DCM is lack of specific treatments at present,and traditional therapy is not such effective in improving the long-term effect for patients. We explored the clinical effectiveness of trimetazidine on the treatment of dilated cardiomyopathy(DCM) associated with chronic congestive heart failure(CHF) by this way.Methods:100patients with DCM associated with CHF were included and divided into2groups:the control group(n=50) and the treatment group (n=50). Patients who had administrated trimetazidine were assigned into the treatment group, while patients without trimetazidine administration were assigned into the control group. The rest treatments remain the same in2groups. The treatment period lasted24weeks. We studied Heart function grade of NYHA, left ventricular ejection fraction(LVEF),and left ventricular end diastolic diameter (LVEDD) before and after treatment in both groups.Results:①In the control group, treatment outcomes of8patients were significant effective,28patients were effective and14patients were noneffective, the total effective rate was72.00%(36/50); In the treatment group, outcomes of13patients were significant effective,31patients were effective and6patients were noneffective, the total effective rate was88.00%(44/50). The total effective rate of the treatment group was significantly higher than the control group(P＜0.05)(2)Comparison of the echocardiography index of the two groups before and after the treatment:The average LVEF of the observe group was (32.7±7.0)%, the average LVEDD was (62.7±5.2)mm before treatment; The average LVEF of the control group was (32.5±6.1)%before treatment, the average LVEDD was (61.9±5.3)mm. The difference of the same index between the two groups have no statistical significance before treatment(P＞0.05). The results after24weeks treatment:The average LVEF of the treatment group rose from (32.7±7.0)%to (44.1±5.9)%, the average LVEDD declined from (62.7±5.2)mm to (55.4±4.5)mm; The average LVEF of the control group increased from (32.5±6.1)%to (40.9±6.4)%, the average LVEDD decreased from (61.9±5.3)mm to (56.±4.6)mm. LVEF and LVEDD of all the patients were improved significantly than before treatment(P＜0.01), LVEF of the observer group was significantly higher than the control group(P＜0.01),LVEDD of the observer group was significantly lower than the control group(P＜0.01).Conclusion:1. Trimetazidine can improve left ventricular systolic function in DCM patients and the treatment efficiency of those who accept beta blockers, ACEI, diuretics and other basic treatment.2. Trimetazidine may improve24weeks long-term prognosis in DCM patients..3.Trimetazidine doesn’t increase adverse reactions in DCM patients associated with heat failure. |
